Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedApr 30, 2026
DataAggregated Company Financials
Companies550
- 7D-4.3%
- 3M-2.0%
- 1Y27.9%
- YTD1.3%
Over the last 7 days, the Biotech industry has dropped 4.3%, driven by Regeneron Pharmaceuticals declining 10%. Over the past 12 months, the industry was up 28%. As for the next few years, earnings are expected to grow by 23% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 30 Apr 2026 | US$1.3t | US$165.6b | -US$11,778,490,982.68 | 16.1x | -107.6x | 7.7x |
| Sat, 28 Mar 2026 | US$1.3t | US$166.1b | -US$13,445,530,937.44 | 15.1x | -93.8x | 7.6x |
| Mon, 23 Feb 2026 | US$1.3t | US$168.1b | -US$13,480,215,246.90 | 22.1x | -99.4x | 8x |
| Wed, 21 Jan 2026 | US$1.2t | US$163.5b | -US$15,162,101,641.93 | 19.8x | -80.7x | 7.5x |
| Fri, 19 Dec 2025 | US$1.2t | US$163.6b | -US$15,778,364,494.15 | 21x | -76.7x | 7.4x |
| Sun, 16 Nov 2025 | US$1.2t | US$163.8b | -US$16,325,082,351.01 | 17.4x | -72.5x | 7.2x |
| Tue, 14 Oct 2025 | US$1.1t | US$163.4b | -US$18,212,977,741.58 | 16.6x | -62.3x | 6.9x |
| Thu, 11 Sep 2025 | US$1.1t | US$163.5b | -US$18,332,644,582.89 | 15.2x | -59.2x | 6.6x |
| Sat, 09 Aug 2025 | US$1.0t | US$162.9b | -US$15,182,045,228.36 | 13.2x | -66.3x | 6.2x |
| Mon, 07 Jul 2025 | US$960.2b | US$155.8b | -US$23,415,675,000.56 | 17.3x | -41x | 6.2x |
| Wed, 04 Jun 2025 | US$922.8b | US$155.9b | -US$23,951,572,272.44 | 15.9x | -38.5x | 5.9x |
| Fri, 02 May 2025 | US$808.2b | US$119.4b | -US$30,863,458,745.12 | 20.6x | -26.2x | 6.8x |
| Sun, 30 Mar 2025 | US$816.7b | US$118.6b | -US$36,963,437,893.60 | 24.4x | -22.1x | 6.9x |
| Tue, 25 Feb 2025 | US$863.5b | US$117.3b | -US$37,621,182,300.47 | 16.8x | -23x | 7.4x |
| Thu, 23 Jan 2025 | US$968.7b | US$149.5b | -US$26,308,060,833.40 | 17.3x | -36.8x | 6.5x |
| Sat, 21 Dec 2024 | US$947.6b | US$149.9b | -US$26,392,835,378.38 | 15.2x | -35.9x | 6.3x |
| Mon, 18 Nov 2024 | US$991.1b | US$150.0b | -US$26,801,381,083.88 | 17.2x | -37x | 6.6x |
| Wed, 16 Oct 2024 | US$905.5b | US$113.1b | -US$36,033,769,973.82 | 21.7x | -25.1x | 8x |
| Fri, 13 Sep 2024 | US$906.6b | US$113.2b | -US$35,840,476,743.75 | 22.7x | -25.3x | 8x |
| Sun, 11 Aug 2024 | US$862.3b | US$112.7b | -US$36,840,475,721.78 | 21.6x | -23.4x | 7.7x |
| Tue, 09 Jul 2024 | US$1.1t | US$164.5b | -US$28,072,591,965.78 | 28.2x | -40.3x | 6.9x |
| Thu, 06 Jun 2024 | US$1.1t | US$164.6b | -US$26,649,807,121.82 | 28.1x | -42.6x | 6.9x |
| Sat, 04 May 2024 | US$1.1t | US$163.7b | -US$26,731,775,868.34 | 24.3x | -41.9x | 6.8x |
| Mon, 01 Apr 2024 | US$1.2t | US$164.4b | -US$23,612,220,177.66 | 24x | -50x | 7.2x |
| Wed, 28 Feb 2024 | US$1.2t | US$167.3b | -US$21,469,811,290.45 | 13.8x | -55.3x | 7.1x |
| Fri, 26 Jan 2024 | US$1.4t | US$204.7b | -US$22,591,368,127.00 | 18.5x | -63.1x | 7x |
| Sun, 24 Dec 2023 | US$1.4t | US$204.9b | -US$22,149,017,627.00 | 19.4x | -61.9x | 6.7x |
| Tue, 21 Nov 2023 | US$1.2t | US$204.7b | -US$22,041,856,134.00 | 18.1x | -55.4x | 6x |
| Thu, 19 Oct 2023 | US$1.3t | US$207.3b | -US$13,074,578,847.00 | 17.1x | -95.7x | 6x |
| Sat, 16 Sep 2023 | US$1.3t | US$207.5b | -US$12,636,400,679.00 | 17.6x | -101.2x | 6.2x |
| Mon, 14 Aug 2023 | US$1.3t | US$207.7b | -US$12,468,580,885.00 | 16.6x | -103.3x | 6.2x |
| Wed, 12 Jul 2023 | US$1.1t | US$186.4b | -US$16,009,595,226.00 | 13.3x | -70.2x | 6x |
| Fri, 09 Jun 2023 | US$1.2t | US$186.1b | -US$15,982,663,871.00 | 11.8x | -72x | 6.2x |
| Sun, 07 May 2023 | US$1.2t | US$192.6b | -US$12,085,119,722.00 | 15.6x | -97.1x | 6.1x |
Price to Earnings Ratio
-97.1x
Current Industry PE
- Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 6.8x is lower than the industry's current PS ratio of 7.7x.
Past Earnings Growth
- Losses for companies in the Biotechs industry have remained mostly flat over the last three years.
- Meanwhile revenues for these companies have declined 4.9% per year.
- This means that the cost of doing business could be reducing since sales have declined but losses haven't fallen much further.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -0.18% | |
| Healthcare | -2.94% | |
| Biotech | -4.33% | |
| Biotech | -4.33% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ABBV AbbVie | US$203.89 | 1.7% +US$6.0b | 4.5% | PE86.2x | |
| RVMD Revolution Medicines | US$140.55 | 4.5% +US$1.3b | 245.8% | PB18.1x | |
| BIIB Biogen | US$194.38 | 3.5% +US$1.1b | 60.7% | PE22.2x | |
| INCY Incyte | US$99.10 | 3.8% +US$796.1m | 59.8% | PE13.8x | |
| KNSA Kiniksa Pharmaceuticals International | US$52.99 | 23.1% +US$763.9m | 91.0% | PE69x |